相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
Michiko Yamato et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Yifei Wang et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
Liam Jenkins et al.
CANCER RESEARCH (2022)
The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target
Pinar cakilkaya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
Ute Jungwirth et al.
NATURE COMMUNICATIONS (2021)
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
Chisato M. Yamazaki et al.
NATURE COMMUNICATIONS (2021)
Antibody Conjugates for Sarcoma Therapy: How Far along Are We?
Letizia Polito et al.
BIOMEDICINES (2021)
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
William D. Tap et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
Ricarda M. Hoffmann et al.
SCIENTIFIC REPORTS (2020)
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Francesca Zammarchi et al.
BLOOD (2018)
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
James W. Purcell et al.
CANCER RESEARCH (2018)
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Mahendra P. Deonarain et al.
ANTIBODIES (2018)
The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers
Christoffer Fagernaes Nielsen et al.
ONCOTARGET (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180
Lars H. Engelholm et al.
JOURNAL OF PATHOLOGY (2016)
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Michael Roth et al.
PEDIATRIC BLOOD & CANCER (2016)
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells
Khin Thway et al.
BRITISH JOURNAL OF CANCER (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database
Kyle R. Duchman et al.
CANCER EPIDEMIOLOGY (2015)
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Shang-Fan Yu et al.
CLINICAL CANCER RESEARCH (2015)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
Esther C. W. Breij et al.
CANCER RESEARCH (2014)
Initial Testing (Stage 1) of the Antibody-Maytansinoid Conjugate, IMGN901 (Lorvotuzumab Mertansine), by the Pediatric Preclinical Testing Program
Andrew C. Wood et al.
PEDIATRIC BLOOD & CANCER (2013)
Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells
Satoshi Takahashi et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Advances in sarcoma genomics and new therapeutic targets
Barry S. Taylor et al.
NATURE REVIEWS CANCER (2011)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Jordi Barretina et al.
NATURE GENETICS (2010)
A Role for Fibrillar Collagen Deposition and the Collagen Internalization Receptor Endo180 in Glioma Invasion
Ivo J. Huijbers et al.
PLOS ONE (2010)
Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
S. Bielack et al.
ANNALS OF ONCOLOGY (2009)
The collagen receptor endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo
Dirk Wienke et al.
CANCER RESEARCH (2007)
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mark Barok et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry
M Wachtel et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV
L Kjoller et al.
EXPERIMENTAL CELL RESEARCH (2004)
A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies
CI Spiridon et al.
CLINICAL CANCER RESEARCH (2004)
Identification and characterization of the endocytic transmembrane glycoprotein Endo180 as a novel collagen receptor
D Wienke et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis
J Sturge et al.
JOURNAL OF CELL BIOLOGY (2003)
A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake
L East et al.
EMBO REPORTS (2003)
uPARAP/Endo 180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion
LH Engelholm et al.
JOURNAL OF CELL BIOLOGY (2003)
The C-type lectin receptor Endo180 displays internalization and recycling properties distinct from other members of the mannose receptor family
MJ Howard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
